Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | ESMO 2023 highlights in genitourinary cancer

Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, shares highlights from the European Society for Medical Oncology (ESMO) 2023 Congress with regard to genitourinary cancers, including data that shows that enfortumab vedotin plus pembrolizumab significantly improves overall-survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in patients with metastatic urothelial carcinoma (KEYNOTE-A39; NCT04223856). This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.